Skip Navigation


NDT Advance Access originally published online on February 19, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/5/1032    most recent
gfh105v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Afzali, B.
Right arrow Articles by Goldsmith, D. J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Afzali, B.
Right arrow Articles by Goldsmith, D. J. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2004) 19: 1032-1036
Nephrol Dial Transplant Vol. 19 No. 5 © ERA-EDTA 2004; all rights reserved

Editorial Comment

Beneficial effects of statins on the kidney: the evidence moves from mouse to man

Behdad Afzali, Ali A. Haydar, Katie Vinen and David J. A. Goldsmith

Renal Medicine and Transplantation, Guy's Hospital, London, UK

Correspondence and offprint requests to: David Goldsmith, MA, FRCP, Consultant Nephrologist, Renal Medicine and Transplantation, Guy's Hospital, London SE1 9RT, UK. Email: david.goldsmith@gstt.sthames.nhs.uk

Keywords: cholesterol; chronic renal failure; glomerulosclerosis; progression; statins

The first 150 words of the full text of this article appear below.



   Introduction
 
The decline in renal function in healthy humans begins after maturity and is reflected in a fairly constant decrease in glomerular filtration, which in 40–60-year-olds averages 8 ml/min lost glomerular filtration rate (GFR) (6%) per decade as determined by endogenous creatinine clearance (CrCl) [1]. Prevention of the development, or progression, of chronic renal failure is the holy grail of nephrology and while success depends in part on the screening and detection of underlying renal disorders, systemic diseases, namely hypertension and diabetes mellitus, remain the commonest causes of end-stage renal failure. Early detection of renal disease is very feasible in both settings by using microalbuminuria as a marker of cardiovascular and renal risk.

Control of blood pressure (BP) has become the cornerstone of ‘nephroprotection’ [2]. ACE inhibitors and angiotensin receptor blockers have achieved primus inter pares status amongst anti-hypertensives, with suggestions that their actions go further than . . . [Full Text of this Article]



   The impact of dyslipidaemia on normal renal function
 


   Statin trials in patients with chronic renal failure
 


   Statin trials in patients with hypertension or dyslipidaemia and normal/near-normal renal function
 


   Conclusions
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
M. Goicoechea, S. G. de Vinuesa, V. Lahera, V. Cachofeiro, F. Gomez-Campdera, A. Vega, S. Abad, and J. Luno
Effects of Atorvastatin on Inflammatory and Fibrinolytic Parameters in Patients with Chronic Kidney Disease
J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S231 - S235.
[Abstract] [Full Text] [PDF]